Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Payables (2016 - 2025)

Historic Payables for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $24.9 million.

  • Coherus Oncology's Payables rose 1370.3% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.9 million, marking a year-over-year increase of 1370.3%. This contributed to the annual value of $28.5 million for FY2024, which is 1920.27% down from last year.
  • Coherus Oncology's Payables amounted to $24.9 million in Q3 2025, which was up 1370.3% from $37.6 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Payables peaked at $126.7 million during Q3 2021, and registered a low of $9.9 million during Q3 2022.
  • Over the past 5 years, Coherus Oncology's median Payables value was $29.3 million (recorded in 2023), while the average stood at $41.4 million.
  • As far as peak fluctuations go, Coherus Oncology's Payables skyrocketed by 95658.88% in 2021, and later plummeted by 9217.19% in 2022.
  • Over the past 5 years, Coherus Oncology's Payables (Quarter) stood at $16.2 million in 2021, then dropped by 28.67% to $11.5 million in 2022, then skyrocketed by 205.56% to $35.2 million in 2023, then fell by 19.2% to $28.5 million in 2024, then decreased by 12.52% to $24.9 million in 2025.
  • Its Payables stands at $24.9 million for Q3 2025, versus $37.6 million for Q2 2025 and $40.9 million for Q1 2025.